Menu Top Menu
  • 48,509.87-524.8-1.08%
  • 14,343.60-90.1-0.63%
Processing
Aurobindo Pharma Ltd (Pharmaceuticals)Last traded on( 15/Jan/2021)

Latest Price Information

Current Price
936.0
Previous Close
959.25
Open Price
950.55
High Price
955.0
Low Price
924.3
Close Price
936.0

Company Announcements

AnnouncementsDate
Updates AUROPHARMA : Aurobindo Pharma Limited has informed the Exchange regarding We refer to our earlier letter dated October 17, 2020 informing about entering into a share purchase agreement to acquire 100% equity share capital of MViyeS Pharma Ventures Private Limited (MViyeS).09/Nov/2020
We refer to our earlier letter dated October 17 2020 informing about entering into a share purchase agreement to acquire 100% equity share capital of MViyeS Pharma Ventures Private Limited (MViyeS). In this regard we would like to inform you that the aforesaid acquisition has been completed on November 6 2020. Before acquisition MViyeS was holding 32.18% shareholding in Eugia Pharma Specialities Limited a joint venture company in which the Company is holding the balance 67.82%. Now both Eugia Pharma Specialities Limited and MViyeS Pharma Ventures Private Limited have become 100% subsidiaries of the Company.07/Nov/2020
We would like to inform that the Company has entered into a share purchase agreement today to acquire 100% equity share capital of MViyeS Pharma Ventures Private Limited (MViyeS). MViyeS is holding 32.18% shareholding in Eugia Pharma Specialities Limited a joint venture company in which the Company is holding 67.82%. By this acquisition both Eugia Pharma Specialities Limited and MViyeS Pharma Ventures Private Limited will become 100% subsidiaries of the Company. The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 and Part A of Schedule III of the aforesaid regulations is enclosed as Annexure I.17/Oct/2020
Updates AUROPHARMA : Aurobindo Pharma Limited has informed the Exchange regarding We refer to our earlier letter dated November 28, 2019 informing about entering into a definitive agreement to acquire certain business assets from Profectus BioSciences Inc., USA., a clinical-stage vaccine development company by Auro Vaccines LLC, 100% subsidiary of Aurobindo Pharma USA Inc., USA, which in turn is 100% subsidiary of the Company.13/Feb/2020
customer.care@askkuber.com
Processing